Indian pharmaceutical company Cipla Limited (BSE:500087) (NSE:CIPLA-EQ) and its US subsidiary Cipla USA Inc announced on Thursday that the US Food and Drug Administration (FDA) has given final approval for the Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Inhalation Aerosol, 90 mcg per actuation.
Cipla said that the product is the first AB–rated generic therapeutic equivalent of Ventolin HFA, marketed by GlaxoSmithKline.
Albuterol Sulfate Inhalation Aerosol is indicated for the treatment or prevention of bronchospasm in adult and paediatric patients aged four years and older with reversible obstructive airway disease, as well as for the prevention of exercise-induced bronchospasm in patients aged four years and older.
According to IQVIA, the total US albuterol market is valued at approximately USD1.5bn.
This approval enhances Cipla's US respiratory portfolio, with approved generics for both Ventolin HFA and Proventil HFA.
Philips secures FDA clearance for Spectral CT Verida system
GSK strengthens pulmonary hypertension pipeline with USD950m acquisition of 35Pharma
hVIVO signs influenza human challenge trial agreement with Traws Pharma
GSK reports strong early-stage data for B7-H4 ADC in gynaecological cancers
FDA grants priority review to ifinatamab deruxtecan in small cell lung cancer
GSK secures China approval for Exdensur to treat nasal polyp condition
Dexcel Pharma's Nintedanib Capsules approved for US launch
Gilead to acquire Tubulis to expand ADC oncology capabilities
Sanofi reports positive phase 2 results for lunsekimig in asthma and CRSwNP